Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shengui capsule in heart failure with preserved ejection fraction
ChiCTR2200058221Phase 4Not yet recruiting
- Sponsor
- Beijing University of Chinese Medicine
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Shengui capsule in heart failure with preserved ejection fraction (HFpEF) and coronary arteriosclerosis (2 arms), sponsored by Beijing University of Chinese Medicine. Primary endpoints: Kansas City Cardiomyopathy Questionnaire (KCCQ) and Six-minute walk test. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
Shengui capsule
03
Conditions
heart failure with preserved ejection fraction (HFpEF)coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2200058221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058221.